Table 1.
Clinicopathologic features at study baseline
| Patient characteristic | Treatment naïve n = 264 | Prior treatment n = 521 | p value |
|---|---|---|---|
| Median age at sorafenib initiation (range), years | 68.6 (59.9–76.2) | 69.5 (61.4–76.6) | 0.309 |
| Gender | |||
| Male | 204 (77.3%) | 426 (81.8%) | 0.135 |
| Female | 60 (22.7%) | 95 (18.2%) | |
| Aetiology | |||
| Hepatitis B virus | 58 (22.0%) | 125 (24.0%) | 0.003 |
| Hepatitis C virus | 76 (28.8%) | 203 (39.0%) | |
| Non-viral | 130 (49.2%) | 193 (37.0%) | |
| Geography | |||
| Western | 197 (74.6%) | 282 (54.1%) | <0.001 |
| Eastern | 67 (25.4%) | 239 (45.9%) | |
| Extrahepatic spread | |||
| Absent | 162 (63.3%) | 317 (61.4%) | 0.619 |
| Present | 94 (36.7%) | 199 (38.6%) | |
| Portal vein invasion | |||
| Absent | 170 (64.4%) | 397 (76.2%) | <0.001 |
| Present | 94 (35.6%) | 124 (23.8%) | |
| α-Fetoprotein | |||
| >400 ng/mL | 121 (46.9%) | 181 (36.0%) | 0.004 |
| <400 ng/mL | 137 (53.1%) | 322 (64.0%) | |
| Child-Pugh class | |||
| A | 117 (47.2%) | 283 (57.3%) | 0.009 |
| B | 131 (52.8%) | 211 (42.7%) | |
| BCLC stage | |||
| A/B | 80 (30.3%) | 209 (40.1%) | 0.007 |
| C | 184 (69.7%) | 312 (59.9%) | |
| Median duration of sorafenib treatment (range), months | 2.9 (1.6–6.9) | 2.6 (1.4–6.9) | 0.755 |
| Previous treatment | |||
| Liver resection | - | 148 (28.4%) | - |
| Liver transplant | - | 7 (1.3%) | |
| RFA | - | 168 (32.2%) | |
| TACE | - | 413 (79.3%) | |
Bold type denotes significance. BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.